Prostate Cancer

PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study. July 3, 2022

Comparison of prostate cancer detection rate at targeted biopsy of hub and spoke centers mpMRI: experience matters. July 1, 2022

Two Specialists, Two Recommendations: Discordance between Urologists' & Radiation Oncologists' Prostate Cancer Treatment Recommendations. July 1, 2022

Post-diagnostic Inflammatory, Hyperinsulinemic, and Insulin Resistant Diets and Lifestyles and the Risk of Prostate Cancer Progression and Mortality. July 1, 2022

Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer. July 1, 2022

Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. July 1, 2022

PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers. July 1, 2022

Novartis Resumes Production and Delivery of Radioligand Therapy Medicines Ahead of Schedule June 30, 2022

Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia. June 30, 2022

The impact of radical prostatectomy on the social well-being of prostate cancer survivors: A qualitative meta-synthesis. June 30, 2022

Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes. June 30, 2022

Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719). June 30, 2022

WHO Classification of Tumours 5th Edition: Evolving Issues in Classification, Diagnosis and Prognostication of Prostate Cancer. June 30, 2022

Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer. June 29, 2022

Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue. June 29, 2022

Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence. June 29, 2022

Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer. June 29, 2022

Does testosterone mediate the relationship between vitamin D and prostate cancer progression? A systematic review and meta-analysis. June 29, 2022

Effects of a multicomponent resistance-based exercise program with protein, vitamin D and calcium supplementation on cognition in men with prostate cancer treated with ADT: secondary analysis of a 12-month randomised controlled trial. June 28, 2022

Safety and efficacy of MRI-guided transurethral ultrasound ablation for radiorecurrent prostate cancer in the presence of gold fiducial markers. June 28, 2022

Page 1 of 1232

email news signup